zika
viru
zikv
mosquitoborn
singl
strand
rna
flaviviru
first
identifi
zika
forest
uganda
rhesu
monkey
case
human
infect
report
africa
asia
first
major
outbreak
island
yap
feder
state
micronesia
zikv
spread
american
contin
emerg
associ
descript
sever
neurolog
complic
syndrom
gb
adult
french
polynesia
microcephali
neonat
brazil
zikvinfect
patient
asymptomat
hand
symptom
almost
indistinguish
caus
undifferenti
system
febril
ill
especi
dengu
denv
chikungunya
viru
infect
confus
issu
infect
also
transmit
aed
mosquito
found
region
zikv
infect
furthermor
coinfect
virus
also
report
addit
viral
infect
could
share
transmiss
rout
zikv
primarili
transmit
peopl
bite
infect
aed
mosquito
mainli
aed
aegypti
aed
albopictu
mosquito
transmit
dengu
chikungunya
yellow
fever
virus
sexual
transmiss
transmiss
laboratori
exposur
possibl
also
theoret
possibl
blood
transfus
organ
tissu
transplant
fertil
treatment
breast
feed
interestingli
zikv
also
transmit
nonvectorborn
rout
includ
sexual
intercours
transplacent
transmiss
blood
product
transfus
possibl
exposur
bodili
fluid
high
viral
load
thu
diagnosi
zikv
infect
reliabl
establish
clinic
featur
alon
evidenc
number
recent
emerg
viral
epidem
highli
sensit
specif
laboratori
diagnost
infect
essenti
infect
control
measur
revers
transcriptasepcr
rtpcr
commonli
use
laboratori
diagnost
assay
zikv
infect
worldwid
number
specif
realtim
convent
rtpcr
assay
target
envelop
e
premembran
prm
nonstructur
protein
gene
code
region
zikv
genom
describ
howev
assay
develop
zikv
epidem
occur
america
potenti
nucleotid
mismatch
sequenc
individu
assay
primer
current
epidem
viru
strain
low
sensit
assay
may
also
lead
falseneg
result
patient
especi
low
viral
load
blood
urin
thu
laboratori
diagnosi
zikv
infect
import
remain
challeng
due
limit
time
window
possibl
viru
detect
wherebi
patient
test
week
postsymptom
onset
difficult
diagnos
therefor
need
accur
diagnost
approach
prolong
diagnost
period
studi
develop
rdt
kit
zika
rdt
detect
iggigm
antibodi
zikv
use
monoclon
antibodi
e
protein
zikv
studi
perform
regul
irb
committe
femptec
irb
committe
bahiafarma
research
adher
tenet
declar
helsinki
particip
provid
written
inform
consent
minor
involv
studi
procedur
handl
mice
conduct
approv
protocol
institut
anim
care
use
committe
iacuc
school
medicin
cathol
univers
korea
adher
regul
set
korean
nation
anim
protect
act
nonstructur
envelop
e
protein
use
diagnost
target
antizikv
particular
sequenc
aa
e
sequenc
aa
obtain
swiss
institut
bioinformat
http
viralzoneexpasyorg
produc
recombin
e
protein
zikv
recombin
baculoviru
express
vector
technolog
cell
vector
clone
briefli
spodoptera
frugiperda
cell
atcc
grown
serumfre
medium
gibcobrl
gaithersburg
maryland
usa
fetal
bovin
serum
fb
cell
transfect
vector
polyfectmedi
method
hilden
qiagen
germani
cell
incub
hr
infect
recombin
baculovirus
multipl
infect
moi
follow
day
incub
cell
remov
cultur
medium
supernat
collect
analyz
sdspage
western
blot
cold
centrifug
g
min
collect
supernat
introduc
preequilibr
acid
ninta
resin
qiagen
elut
perform
use
mmoll
imidazol
mmoll
triscl
ph
eluat
dialyz
use
triscl
ph
hr
chang
buffer
thrice
western
blot
zika
posit
antihigghrp
sdspage
perform
purif
recombin
protein
mix
equal
volum
freund
complet
adjuv
sigma
chemic
co
st
loui
missouri
usa
mixtur
inject
intraperiton
femal
balbc
mice
samtaco
suwon
korea
second
third
inject
follow
amount
protein
mix
incomplet
freund
adjuv
sigmaaldrich
st
loui
missouri
usa
way
interv
third
immun
recombin
protein
inject
intraven
without
adjuv
produc
hybridoma
cellsecret
monoclon
antibodi
mab
use
cell
fusion
techniqu
accord
establish
protocol
mous
myeloma
cell
cell
atcc
crl
fuse
spleen
cell
donor
mice
use
polyethylen
glycol
sigma
chemic
co
incub
hypoxanthin
aminopterin
thymidin
media
sigma
chemic
co
supernat
hybridoma
cell
cultur
screen
elisa
use
recombin
zikv
e
protein
antigen
subclon
limit
dilut
select
hybridoma
coloni
transfer
tissu
cultur
flask
nunc
roskild
denmark
medium
gibcobrl
contain
fb
gibcobrl
mabcontain
supernat
ascit
fluid
balbc
mice
collect
screen
use
elisa
determin
antibodi
properti
mab
purifi
protein
g
agaros
resin
amicogen
inc
jinju
korea
identifi
use
sdspolyacrylamid
gel
electrophoresi
western
blot
mab
isotyp
determin
use
goat
antimous
immunoglobulin
sigmaaldrich
accord
manufactur
instruct
indirect
competit
elisa
conduct
measur
affin
mab
previous
describ
variou
concentr
recombin
e
antigen
incub
mab
hr
room
temperatur
rt
mixtur
transfer
well
recombin
antigen
coat
incub
rt
well
rins
pb
contain
incub
follow
antimous
igghorseradish
peroxidas
hrp
conjug
rt
solut
ad
final
wash
final
absorb
measur
micropl
reader
benchmark
plu
biorad
hercul
california
usa
nm
termin
color
reaction
dissoci
constant
kd
calcul
gener
klotz
plot
monoclon
antibodi
e
protein
select
hybridoma
conjug
colloid
gold
particl
nm
mean
diamet
accord
previous
describ
procedur
produc
zika
iggigm
rdt
kit
zika
rdt
fig
briefli
assay
perform
ad
serumplasma
whole
blood
drop
assay
buffer
react
band
read
min
densiti
determin
arbitrarili
definit
reactiv
determin
mid
weaker
stronger
reactiv
compar
determin
weak
strong
final
result
agre
upon
investig
fig
investig
analyt
sensit
rdt
comparison
elisa
plaqu
reduct
neutral
test
prnt
pcr
perform
zika
posit
specimen
provid
hospit
gaffre
e
guinl
rio
de
janeiro
brazil
realtim
rtpcr
realstar
zika
rtpcr
kit
accupow
zika
realtim
rtpcr
kit
method
offici
approv
use
gold
standard
diagnost
method
supernat
sampl
serum
sampl
sampl
diluent
appli
well
elisa
sampl
consid
posit
optic
densiti
od
nm
spectrophotomet
perkin
elmer
turku
finland
greater
blank
pb
sampl
cutoff
valu
set
twice
averag
valu
blank
sampl
replic
prnt
perform
determin
presenc
virusspecif
neutral
antibodi
pair
serum
sampl
briefli
vero
cell
seed
densiti
cellswel
hr
infect
plate
decompl
sera
sampl
min
fold
serial
dilut
dmem
serumfre
medium
equal
volum
dmemdilut
zika
viru
contain
pfu
ad
incub
hr
final
volum
vero
cell
infect
duplic
neutral
mixtur
incub
hr
afterward
viral
inoculum
remov
cell
overlaid
ml
dmem
fb
seaplaqu
agaros
lonza
plate
incub
day
period
cell
wash
twice
pb
stain
crystal
violet
min
plaqu
count
percentag
plaqu
reduct
control
serum
calcul
rna
extract
serum
sampl
prepar
pcr
use
exiprep
viral
rna
kit
bioneer
co
daejeon
korea
viral
rna
extract
serum
elut
elut
buffer
accupow
zikv
multiplex
realtim
rtpcr
assay
rna
extract
mix
master
mix
realtim
rtpcr
perform
use
pcr
thermocycl
exicycl
realtim
quantit
thermal
block
bioneer
co
korea
procedur
perform
accord
manufactur
instruct
posit
sampl
kindli
provid
hospit
gaffre
e
guinl
rio
de
janeiro
brazil
femptec
foundat
ministri
bahia
brazil
collect
screen
procedur
endem
area
neg
sampl
kindli
provid
dankook
univers
hospit
cheonan
korea
field
test
use
elisa
control
sera
posit
neg
sampl
check
igg
posit
neg
sampl
check
igm
antibodi
titer
elisa
optic
densiti
od
duplic
sampl
measur
nm
spectrophotomet
perkin
elmer
compens
compar
od
standard
posit
serum
plate
cross
reaction
denv
evalu
use
antidengu
mix
titer
perform
panel
cross
reaction
west
nile
yellow
fever
hepat
c
viru
hcv
also
determin
zikv
e
protein
expos
surfac
viru
candid
target
antigen
dna
sequenc
e
obtain
swiss
institut
bioinformat
http
viralzoneexpasyorg
clone
amino
acid
e
amino
acid
protein
sequenc
locat
adjac
genom
use
sequenc
zikv
protein
success
express
cell
purifi
kda
molecular
weight
fig
monoclon
antibodi
show
high
affin
constant
recombin
protein
select
among
variou
hybridoma
type
hybridoma
show
fold
strong
affin
recombin
e
antigen
compar
isotyp
hybridoma
hand
hybridoma
show
even
stronger
respons
recombin
antigen
fold
strong
affin
protein
compar
isotyp
hybridoma
fig
tabl
evalu
usag
zika
iggigm
rdt
kit
reliabl
diagnost
tool
comparison
test
use
zika
mix
titer
standard
show
ident
result
rdt
kit
elisa
prnt
pcr
fig
tabl
diagnost
accuraci
zika
rdt
determin
sensit
specif
field
test
fairli
high
sensit
specif
igg
respect
igm
respect
tabl
cross
reaction
denv
also
determin
zika
rdt
show
crossreact
igg
igm
respect
total
panel
tabl
result
show
cross
reaction
identifi
high
titer
sco
denv
antibodi
posit
fortun
crossreact
antiwest
nile
viru
antiyellow
fever
viru
antihcv
observ
detect
zikv
rna
earli
cours
ill
realtim
rtpcr
rrtpcr
serum
urin
commonli
use
first
week
onset
ill
although
number
realtim
zikv
rtpcr
assay
describ
recent
evalu
show
low
sensit
incompat
current
circul
epidem
zikv
strain
belong
asianamerican
lineag
addit
estim
zikvinfect
patient
may
undiagnos
low
viral
load
patient
clinic
specimen
thu
serolog
test
zikv
detect
zikvspecif
igm
neutral
antibodi
develop
sinc
igm
neutral
antibodi
zikv
detect
week
onset
ill
serolog
test
follow
zikv
rna
neg
serum
urin
suspici
zikv
infect
patient
present
studi
success
appli
gold
conjug
develop
rapid
diagnost
test
rdt
system
monoclon
antibodi
correspond
envelop
e
nonstructur
protein
zikv
respect
serolog
diagnosi
zikv
far
easi
extens
crossreact
antibodi
flavivirus
baculoviru
express
system
obtain
solubl
express
highli
purifi
recombin
e
protein
zikv
result
sensit
specif
zika
rdt
excel
zika
rdt
show
ident
result
standard
panel
use
elisa
prnt
zika
rdt
requir
neither
electr
specif
laboratori
equip
stabl
long
shelf
life
simpl
use
assay
fast
avoid
blood
drawn
suspici
patient
characterist
make
use
field
set
howev
crossreact
denv
igg
igm
respect
observ
fortun
crossreact
antiwest
nile
viru
antiyellow
fever
viru
antihcv
serum
flaviviru
secret
infect
cell
involv
immun
evas
pathogenesi
distinct
featur
may
relat
zikv
neurotrop
e
protein
differ
electrostat
characterist
protein
would
result
high
efficaci
rdt
differenti
flaviviru
infect
crossreact
denv
repres
major
disadvantag
test
presum
caus
crossreact
zika
rdt
denv
may
caus
mix
infect
zikv
denv
vector
human
overlap
clinic
symptom
make
differenti
diagnosi
problem
zikv
denv
show
higher
homolog
e
protein
common
antigen
determin
may
confus
issu
preexist
immun
prior
denv
infect
might
also
increas
zikv
replic
antibodydepend
enhanc
ade
zikv
infect
caus
variabl
result
context
crossreact
denv
zikv
seem
inevit
inde
suggest
zikv
must
consid
anoth
member
denv
serocomplex
zika
rdt
first
develop
first
receiv
brazilian
health
regulatori
agenc
anvisa
approv
zikv
rapid
test
brazilian
govern
cooper
bahiafarma
bahia
brazil
genbodi
inc
cheonan
korea
prove
effect
field
promot
zikv
test
public
healthcar
awar
facilit
zika
rdt
kit
simpl
use
rapid
assay
sensit
highli
specif
therefor
would
serv
choic
method
pointofcar
diagnosi
larg
scale
survey
zikv
infect
among
peopl
clinic
field
condit
worldwid
endem
area
though
test
prove
effect
studi
need
address
signific
problem
coinfect
denv
zikv
chikungunya
viru
yet
unknown
viral
diseas
need
evalu
coinfect
rate
determin
need
differenti
infect
singl
sampl
clinic
epidemiolog
purpos
immedi
import
like
remain
relev
futur
addit
relationship
zikv
variant
sever
complic
microcephali
guillainbarr
syndrom
also
need
address
test
seem
flexibl
enough
detect
variant
